MedTrace Logo

Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema

NCT01487629 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2011-12-13

No results posted yet for this study

Summary

The purpose of this study is to compare the morphological and visual acuity outcomes associated with 1.5 mg bevacizumab versus 0.5 ranibizumab intravitreal injections for treatment of diabetic macular edema.

Conditions

Interventions

DRUG

Bevacizumab

Bevacizumab, 1.5 mg, intravitreal, throughout the study

DRUG

Ranibizumab

Ranibizumab, 0.5 mg, intravitreal, throughout the study

Sponsors & Collaborators

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

    collaborator OTHER_GOV

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Rodrigo Jorge, MD, PhD · University of Sao Paulo

  • Felipe Almeida, MD · Hospital das Clinicas - Faculdade de Medicina de Ribeirão Preto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01487629 on ClinicalTrials.gov